Skip to main content
Top
Published in: Endocrine 3/2014

01-04-2014 | Original Article

Changes in levels of peripheral hormones controlling appetite are inconsistent with hyperphagia in leptin-deficient subjects

Authors: Sadia Saeed, Paul R. Bech, Tayyaba Hafeez, Rabail Alam, Mario Falchi, Mohammad A. Ghatei, Stephen R. Bloom, Muhammad Arslan, Philippe Froguel

Published in: Endocrine | Issue 3/2014

Login to get access

Abstract

Congenital leptin deficiency, a rare genetic disorder due to a homozygous mutation in the leptin gene (LEP), is accompanied by extreme obesity and hyperphagia. A number of gastrointestinal hormones have been shown to critically regulate food intake but their physiological role in hyperphagic response in congenital leptin deficiency has not been elucidated. This study is the first to evaluate the fasting and postprandial profiles of gut-derived hormones in homozygous and heterozygous carriers of LEP mutation. The study subjects from two consanguineous families consisted of five homozygous and eight heterozygous carriers of LEP mutation, c.398delG. Ten wild-type normal-weight subjects served as controls. Fasting and 1-h postprandial plasma ghrelin, glucagon-like peptide (GLP) 1, peptide YY (PYY), leptin and insulin levels were measured by immunoassays. Fasting plasma ghrelin levels in homozygotes remained remarkably unchanged following food consumption (P = 0.33) in contrast to a significant decline in heterozygous (P < 0.03) and normal (P < 0.02) subjects. A significant postprandial increase in PYY was observed in heterozygous (P < 0.02) and control subjects (P < 0.01), but not in the homozygous group (P = 0.22). A postprandial rise in GLP-1 levels was significant (P < 0.02) in all groups. Interestingly, fasting leptin levels in heterozygotes were not significantly different from controls and did not change significantly following meal. Our results demonstrate that gut hormones play little or no physiological role in driving the hyperphagic response of leptin-deficient subjects. In contrast, fasting and postprandial levels of gut hormones in heterozygous mutation carriers were comparable to those of normal-weight controls.
Literature
1.
go back to reference C. Bjorbaek, B.B. Kahn, Leptin signaling in the central nervous system and the periphery. Recent Prog. Horm. Res. 59, 305–331 (2004)PubMedCrossRef C. Bjorbaek, B.B. Kahn, Leptin signaling in the central nervous system and the periphery. Recent Prog. Horm. Res. 59, 305–331 (2004)PubMedCrossRef
2.
go back to reference A. Oswal, G. Yeo, Leptin and the control of body weight: a review of its diverse central targets, signaling mechanisms, and role in the pathogenesis of obesity. Obesity (Silver Spring) 18, 221–229 (2010)CrossRef A. Oswal, G. Yeo, Leptin and the control of body weight: a review of its diverse central targets, signaling mechanisms, and role in the pathogenesis of obesity. Obesity (Silver Spring) 18, 221–229 (2010)CrossRef
3.
go back to reference K.G. Murphy, S.R. Bloom, Gut hormones and the regulation of energy homeostasis. Nature 444, 854–859 (2006)PubMedCrossRef K.G. Murphy, S.R. Bloom, Gut hormones and the regulation of energy homeostasis. Nature 444, 854–859 (2006)PubMedCrossRef
4.
go back to reference H. Ariyasu, K. Takaya, T. Tagami et al., Stomach is a major source of circulating ghrelin, and feeding state determines plasma ghrelin-like immunoreactivity levels in humans. J. Clin. Endocrinol. Metab. 86, 4753–4758 (2001)PubMedCrossRef H. Ariyasu, K. Takaya, T. Tagami et al., Stomach is a major source of circulating ghrelin, and feeding state determines plasma ghrelin-like immunoreactivity levels in humans. J. Clin. Endocrinol. Metab. 86, 4753–4758 (2001)PubMedCrossRef
5.
go back to reference T.R. Castaneda, J. Tong, R. Datta, M. Culler, M.H. Tschop, Ghrelin in the regulation of body weight and metabolism. Front. Neuroendocrinol. 31, 44–60 (2010)PubMedCrossRef T.R. Castaneda, J. Tong, R. Datta, M. Culler, M.H. Tschop, Ghrelin in the regulation of body weight and metabolism. Front. Neuroendocrinol. 31, 44–60 (2010)PubMedCrossRef
6.
go back to reference P.J. English, M.A. Ghatei, I.A. Malik, S.R. Bloom, J.P. Wilding, Food fails to suppress ghrelin levels in obese humans. J. Clin. Endocrinol. Metab. 87, 2984–2987 (2002)PubMedCrossRef P.J. English, M.A. Ghatei, I.A. Malik, S.R. Bloom, J.P. Wilding, Food fails to suppress ghrelin levels in obese humans. J. Clin. Endocrinol. Metab. 87, 2984–2987 (2002)PubMedCrossRef
7.
go back to reference B. Otto, U. Cuntz, E. Fruehauf, R. Wawarta et al., Weight gain decreases elevated plasma ghrelin concentrations of patients with anorexia nervosa. Eur. J. Endocrinol. 145, 669–673 (2001)PubMedCrossRef B. Otto, U. Cuntz, E. Fruehauf, R. Wawarta et al., Weight gain decreases elevated plasma ghrelin concentrations of patients with anorexia nervosa. Eur. J. Endocrinol. 145, 669–673 (2001)PubMedCrossRef
8.
go back to reference A.A. van der Klaauw, J.M. Keogh, E. Henning, A. Blackwood, A.M. Haqq, J.Q. Purnell, I.S. Farooqi, Postprandial total ghrelin suppression is modulated by melanocortin signaling in humans. J. Clin. Endocrinol. Metab. 98, E288–E292 (2013)PubMedCentralPubMedCrossRef A.A. van der Klaauw, J.M. Keogh, E. Henning, A. Blackwood, A.M. Haqq, J.Q. Purnell, I.S. Farooqi, Postprandial total ghrelin suppression is modulated by melanocortin signaling in humans. J. Clin. Endocrinol. Metab. 98, E288–E292 (2013)PubMedCentralPubMedCrossRef
9.
go back to reference A.M. Haqq, I.S. Farooqi, S. O’Rahilly et al., Serum ghrelin levels are inversely correlated with body mass index, age, and insulin concentrations in normal children and are markedly increased in Prader–Willi syndrome. J. Clin. Endocrinol. Metab. 88, 174–178 (2003)PubMedCrossRef A.M. Haqq, I.S. Farooqi, S. O’Rahilly et al., Serum ghrelin levels are inversely correlated with body mass index, age, and insulin concentrations in normal children and are markedly increased in Prader–Willi syndrome. J. Clin. Endocrinol. Metab. 88, 174–178 (2003)PubMedCrossRef
10.
go back to reference A.P. Goldstone, M. Patterson, N. Kalingag et al., Fasting and postprandial hyperghrelinemia in Prader–Willi syndrome is partially explained by hypoinsulinemia, and is not due to peptide YY3-36 deficiency or seen in hypothalamic obesity due to craniopharyngioma. J. Clin. Endocrinol. Metab. 90, 2681–2690 (2005)PubMedCrossRef A.P. Goldstone, M. Patterson, N. Kalingag et al., Fasting and postprandial hyperghrelinemia in Prader–Willi syndrome is partially explained by hypoinsulinemia, and is not due to peptide YY3-36 deficiency or seen in hypothalamic obesity due to craniopharyngioma. J. Clin. Endocrinol. Metab. 90, 2681–2690 (2005)PubMedCrossRef
11.
go back to reference E. Ekblad, F. Sundler, Distribution of pancreatic polypeptide and peptide YY. Peptides 23, 251–261 (2002)PubMedCrossRef E. Ekblad, F. Sundler, Distribution of pancreatic polypeptide and peptide YY. Peptides 23, 251–261 (2002)PubMedCrossRef
12.
go back to reference R.L. Batterham, H. Heffron, S. Kapoor et al., Critical role for peptide YY in protein-mediated satiation and body-weight regulation. Cell Metab. 4, 223–233 (2006)PubMedCrossRef R.L. Batterham, H. Heffron, S. Kapoor et al., Critical role for peptide YY in protein-mediated satiation and body-weight regulation. Cell Metab. 4, 223–233 (2006)PubMedCrossRef
13.
go back to reference T.E. Adrian, G.L. Ferri, A.J. Bacarese-Hamilton, H.S. Fuessl, J.M. Polak, S.R. Bloom, Human distribution and release of a putative new gut hormone, peptide YY. Gastroenterology 89, 1070–1077 (1985)PubMed T.E. Adrian, G.L. Ferri, A.J. Bacarese-Hamilton, H.S. Fuessl, J.M. Polak, S.R. Bloom, Human distribution and release of a putative new gut hormone, peptide YY. Gastroenterology 89, 1070–1077 (1985)PubMed
14.
go back to reference A.A. van der Klaauw, J.M. Keogh, E. Henning, V.M. Trowse, W.S. Dhillo, M.A. Ghatei, I.S. Farooqi, High protein intake stimulates postprandial GLP1 and PYY release. Obesity (Silver Spring) (2012). doi:10.1002/oby.20154 A.A. van der Klaauw, J.M. Keogh, E. Henning, V.M. Trowse, W.S. Dhillo, M.A. Ghatei, I.S. Farooqi, High protein intake stimulates postprandial GLP1 and PYY release. Obesity (Silver Spring) (2012). doi:10.​1002/​oby.​20154
15.
go back to reference R.A. Pittner, C.X. Moore, S.P. Bhavsar et al., Effects of PYY[3–36] in rodent models of diabetes and obesity. Int. J. Obes. Relat. Metab. Disord. 28, 963–971 (2004)PubMedCrossRef R.A. Pittner, C.X. Moore, S.P. Bhavsar et al., Effects of PYY[3–36] in rodent models of diabetes and obesity. Int. J. Obes. Relat. Metab. Disord. 28, 963–971 (2004)PubMedCrossRef
16.
go back to reference K. Zwirska-Korczala, S.J. Konturek, M. Sodowski et al., Basal and postprandial plasma levels of PYY, ghrelin, cholecystokinin, gastrin and insulin in women with moderate and morbid obesity and metabolic syndrome. J. Physiol. Pharmacol. 58(Suppl 1), 13–35 (2007)PubMed K. Zwirska-Korczala, S.J. Konturek, M. Sodowski et al., Basal and postprandial plasma levels of PYY, ghrelin, cholecystokinin, gastrin and insulin in women with moderate and morbid obesity and metabolic syndrome. J. Physiol. Pharmacol. 58(Suppl 1), 13–35 (2007)PubMed
17.
go back to reference M.D. Turton, D. O’Shea, I. Gunn, S.A. Beak et al., A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 379, 69–72 (1996)PubMedCrossRef M.D. Turton, D. O’Shea, I. Gunn, S.A. Beak et al., A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 379, 69–72 (1996)PubMedCrossRef
19.
go back to reference K.D. Niswender, M.W. Schwartz, Insulin and leptin revisited: adiposity signals with overlapping physiological and intracellular signaling capabilities. Front. Neuroendocrinol. 24, 1–10 (2003)PubMedCrossRef K.D. Niswender, M.W. Schwartz, Insulin and leptin revisited: adiposity signals with overlapping physiological and intracellular signaling capabilities. Front. Neuroendocrinol. 24, 1–10 (2003)PubMedCrossRef
20.
go back to reference M.W. Schwartz, S.C. Woods, D. Porte Jr, R.J. Seeley, D.G. Baskin, Central nervous system control of food intake. Nature 404, 661–671 (2000)PubMed M.W. Schwartz, S.C. Woods, D. Porte Jr, R.J. Seeley, D.G. Baskin, Central nervous system control of food intake. Nature 404, 661–671 (2000)PubMed
21.
go back to reference A.J. van der Lely, M. Tschop, M.L. Heiman, E. Ghigo, Biological, physiological, pathophysiological, and pharmacological aspects of ghrelin. Endocr. Rev. 25, 426–457 (2004)PubMedCrossRef A.J. van der Lely, M. Tschop, M.L. Heiman, E. Ghigo, Biological, physiological, pathophysiological, and pharmacological aspects of ghrelin. Endocr. Rev. 25, 426–457 (2004)PubMedCrossRef
22.
go back to reference C.T. Montague, I.S. Farooqi, J.P. Whitehead et al., Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature 387, 903–908 (1997)PubMedCrossRef C.T. Montague, I.S. Farooqi, J.P. Whitehead et al., Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature 387, 903–908 (1997)PubMedCrossRef
23.
go back to reference I.S. Farooqi, S. O’Rahilly, Monogenic human obesity syndromes. Recent Prog. Horm. Res. 59, 409–424 (2004)PubMedCrossRef I.S. Farooqi, S. O’Rahilly, Monogenic human obesity syndromes. Recent Prog. Horm. Res. 59, 409–424 (2004)PubMedCrossRef
24.
go back to reference S. Saeed, T.A. Butt, M. Anwer, M. Arslan, P. Froguel, High prevalence of leptin and melanocortin-4 receptor gene mutations in children with severe obesity from Pakistani consanguineous families. Mol. Genet. Metab. 106, 121–126 (2012)PubMedCrossRef S. Saeed, T.A. Butt, M. Anwer, M. Arslan, P. Froguel, High prevalence of leptin and melanocortin-4 receptor gene mutations in children with severe obesity from Pakistani consanguineous families. Mol. Genet. Metab. 106, 121–126 (2012)PubMedCrossRef
25.
go back to reference A.I. Blakemore, P. Froguel, Investigation of Mendelian forms of obesity holds out the prospect of personalized medicine. Ann. N. Y. Acad. Sci. 1214, 180–189 (2010)PubMedCrossRef A.I. Blakemore, P. Froguel, Investigation of Mendelian forms of obesity holds out the prospect of personalized medicine. Ann. N. Y. Acad. Sci. 1214, 180–189 (2010)PubMedCrossRef
26.
go back to reference I.S. Farooqi, J.M. Keogh, S. Kamath et al., Partial leptin deficiency and human adiposity. Nature 414, 34–35 (2001)PubMedCrossRef I.S. Farooqi, J.M. Keogh, S. Kamath et al., Partial leptin deficiency and human adiposity. Nature 414, 34–35 (2001)PubMedCrossRef
27.
go back to reference A.M. Wren, L.J. Seal, M.A. Cohen et al., Ghrelin enhances appetite and increases food intake in humans. J. Clin. Endocrinol. Metab. 86, 5992–5995 (2001)PubMedCrossRef A.M. Wren, L.J. Seal, M.A. Cohen et al., Ghrelin enhances appetite and increases food intake in humans. J. Clin. Endocrinol. Metab. 86, 5992–5995 (2001)PubMedCrossRef
28.
go back to reference M. Tschop, C. Weyer, P.A. Tataranni, V. Devanarayan, E. Ravussin, M.L. Heiman, Circulating ghrelin levels are decreased in human obesity. Diabetes 50, 707–709 (2001)PubMedCrossRef M. Tschop, C. Weyer, P.A. Tataranni, V. Devanarayan, E. Ravussin, M.L. Heiman, Circulating ghrelin levels are decreased in human obesity. Diabetes 50, 707–709 (2001)PubMedCrossRef
30.
go back to reference H. Kirchner, K.M. Heppner, J. Holland, D. Kabra, M.H. Tschöp, P.T. Pfluger, Ablation of ghrelin O-acyltransferase does not improve glucose intolerance or body adiposity in mice on a leptin-deficient ob/ob background. PLoS One 8, e61822 (2013)PubMedCentralPubMedCrossRef H. Kirchner, K.M. Heppner, J. Holland, D. Kabra, M.H. Tschöp, P.T. Pfluger, Ablation of ghrelin O-acyltransferase does not improve glucose intolerance or body adiposity in mice on a leptin-deficient ob/ob background. PLoS One 8, e61822 (2013)PubMedCentralPubMedCrossRef
31.
go back to reference B.O. Yildiz, M.A. Suchard, M.L. Wong, S.M. McCann, J. Licinio, Alterations in the dynamics of circulating ghrelin, adiponectin, and leptin in human obesity. Proc. Natl. Acad. Sci. USA. 101, 10434–10439 (2004)PubMedCentralPubMedCrossRef B.O. Yildiz, M.A. Suchard, M.L. Wong, S.M. McCann, J. Licinio, Alterations in the dynamics of circulating ghrelin, adiponectin, and leptin in human obesity. Proc. Natl. Acad. Sci. USA. 101, 10434–10439 (2004)PubMedCentralPubMedCrossRef
32.
go back to reference C. Bizzarri, A.E. Rigamonti, A. Luce et al., Children with Prader–Willi syndrome exhibit more evident meal-induced responses in plasma ghrelin and peptide YY levels than obese and lean children. Eur. J. Endocrinol. 162, 499–505 (2010)PubMedCrossRef C. Bizzarri, A.E. Rigamonti, A. Luce et al., Children with Prader–Willi syndrome exhibit more evident meal-induced responses in plasma ghrelin and peptide YY levels than obese and lean children. Eur. J. Endocrinol. 162, 499–505 (2010)PubMedCrossRef
33.
go back to reference A.P. Goldstone, E.L. Thomas, A.E. Brynes et al., Visceral adipose tissue and metabolic complications of obesity are reduced in Prader–Willi syndrome female adults: evidence for novel influences on body fat distribution. J. Clin. Endocrinol. Metab. 86, 4330–4338 (2001)PubMedCrossRef A.P. Goldstone, E.L. Thomas, A.E. Brynes et al., Visceral adipose tissue and metabolic complications of obesity are reduced in Prader–Willi syndrome female adults: evidence for novel influences on body fat distribution. J. Clin. Endocrinol. Metab. 86, 4330–4338 (2001)PubMedCrossRef
34.
go back to reference L. Purtell, L. Sze, G. Loughnan et al., In adults with Prader–Willi syndrome, elevated ghrelin levels are more consistent with hyperphagia than high PYY and GLP-1 levels. Neuropeptides 4, 301–307 (2011)CrossRef L. Purtell, L. Sze, G. Loughnan et al., In adults with Prader–Willi syndrome, elevated ghrelin levels are more consistent with hyperphagia than high PYY and GLP-1 levels. Neuropeptides 4, 301–307 (2011)CrossRef
35.
36.
go back to reference J.L. Chan, V. Stoyneva, T. Kelesidis, P. Raciti, C.S. Mantzoros, Peptide YY levels are decreased by fasting and elevated following caloric intake but are not regulated by leptin. Diabetologia 49, 169–173 (2006)PubMedCrossRef J.L. Chan, V. Stoyneva, T. Kelesidis, P. Raciti, C.S. Mantzoros, Peptide YY levels are decreased by fasting and elevated following caloric intake but are not regulated by leptin. Diabetologia 49, 169–173 (2006)PubMedCrossRef
37.
go back to reference M. Korbonits, P.J. Trainer, J.A. Little et al., Leptin levels do not change acutely with food administration in normal or obese subjects, but are negatively correlated with pituitary-adrenal activity. Clin. Endocrinol. (Oxf.) 46, 751–757 (1997)CrossRef M. Korbonits, P.J. Trainer, J.A. Little et al., Leptin levels do not change acutely with food administration in normal or obese subjects, but are negatively correlated with pituitary-adrenal activity. Clin. Endocrinol. (Oxf.) 46, 751–757 (1997)CrossRef
38.
go back to reference M. Romon, P. Lebel, J.C. Fruchart, J. Dallongeville, Postprandial leptin response to carbohydrate and fat meals in obese women. J. Am. Coll. Nutr. 22, 247–251 (2003)PubMedCrossRef M. Romon, P. Lebel, J.C. Fruchart, J. Dallongeville, Postprandial leptin response to carbohydrate and fat meals in obese women. J. Am. Coll. Nutr. 22, 247–251 (2003)PubMedCrossRef
39.
go back to reference J. Dallongeville, B. Hecquet, P. Lebel et al., Short term response of circulating leptin to feeding and fasting in man: influence of circadian cycle. Int. J. Obes. Relat. Metab. Disord. 22, 728–733 (1998)PubMedCrossRef J. Dallongeville, B. Hecquet, P. Lebel et al., Short term response of circulating leptin to feeding and fasting in man: influence of circadian cycle. Int. J. Obes. Relat. Metab. Disord. 22, 728–733 (1998)PubMedCrossRef
40.
go back to reference I.S. Farooqi, G. Matarese, G.M. Lord et al., Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. J. Clin. Invest. 110, 1093–1103 (2002)PubMedCentralPubMedCrossRef I.S. Farooqi, G. Matarese, G.M. Lord et al., Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. J. Clin. Invest. 110, 1093–1103 (2002)PubMedCentralPubMedCrossRef
41.
go back to reference J. Levi, S.L. Gray, M. Speck et al., Acute disruption of leptin signaling in vivo leads to increased insulin levels and insulin resistance. Endocrinology 152, 3385–3395 (2011)PubMedCrossRef J. Levi, S.L. Gray, M. Speck et al., Acute disruption of leptin signaling in vivo leads to increased insulin levels and insulin resistance. Endocrinology 152, 3385–3395 (2011)PubMedCrossRef
42.
go back to reference P.R. Flatt, C.J. Bailey, A.M. Cameron, B.J. Gould, Age effects on glycosylated blood proteins in lean and obese hyperglycaemic (ob/ob) mice. Diabetes Res. 3, 241–243 (1986)PubMed P.R. Flatt, C.J. Bailey, A.M. Cameron, B.J. Gould, Age effects on glycosylated blood proteins in lean and obese hyperglycaemic (ob/ob) mice. Diabetes Res. 3, 241–243 (1986)PubMed
43.
go back to reference J. Seufert, T.J. Kieffer, J.F. Habener, Leptin inhibits insulin gene transcription and reverses hyperinsulinemia in leptin-deficient ob/ob mice. Proc. Natl. Acad. Sci. USA. 96, 674–679 (1999)PubMedCentralPubMedCrossRef J. Seufert, T.J. Kieffer, J.F. Habener, Leptin inhibits insulin gene transcription and reverses hyperinsulinemia in leptin-deficient ob/ob mice. Proc. Natl. Acad. Sci. USA. 96, 674–679 (1999)PubMedCentralPubMedCrossRef
44.
go back to reference Y. Sun, M. Asnicar, P.K. Saha, L. Chan, R.G. Smith, Ablation of ghrelin improves the diabetic but not obese phenotype of ob/ob mice. Cell Metab. 3, 379–386 (2006)PubMedCrossRef Y. Sun, M. Asnicar, P.K. Saha, L. Chan, R.G. Smith, Ablation of ghrelin improves the diabetic but not obese phenotype of ob/ob mice. Cell Metab. 3, 379–386 (2006)PubMedCrossRef
Metadata
Title
Changes in levels of peripheral hormones controlling appetite are inconsistent with hyperphagia in leptin-deficient subjects
Authors
Sadia Saeed
Paul R. Bech
Tayyaba Hafeez
Rabail Alam
Mario Falchi
Mohammad A. Ghatei
Stephen R. Bloom
Muhammad Arslan
Philippe Froguel
Publication date
01-04-2014
Publisher
Springer US
Published in
Endocrine / Issue 3/2014
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-013-0009-9

Other articles of this Issue 3/2014

Endocrine 3/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.